What happened with IART today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Integra LifeSciences Holdings supplies hospitals and other healthcare providers with products for surgery and wound treatment, selling globally through its own sales teams and independent distributors. Most revenue comes from Codman Specialty Surgical, chiefly its neurosurgery products. These help surgeons repair the membrane around the brain, remove tissue and manage fluid and pressure inside the skull. The segment also sells surgical instruments and ear, nose and throat devices, including Acclarent products.
The smaller Tissue Technologies business makes materials used to repair skin, wounds and other damaged tissue. It also earns revenue by making regenerative and wound-care products that other companies sell under their own labels, supplying them with raw materials and manufacturing to their specifications.
The business depends on maintaining compliant production and reliable supplies. Some materials and components have only one or a few suppliers, and manufacturing standards can make replacements slow to qualify. Quality problems have already led to recalls and shipping holds. Product approvals determine what Integra can market, and regulators prohibit promotion for uses outside approved or cleared labeling. Healthcare reimbursement and hospitals’ purchasing arrangements also influence what customers will buy and the prices they will pay.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Integra’s results hinge on neurosurgical demand, manufacturing quality and wound-care adoption; B. Braun and Organogenesis are important competitors missing from this list.
Medtronic competes with Integra for healthcare providers’ spending on devices that drain fluid from the brain’s ventricles and monitor pressure. Its new neurosurgical products are worth watching for changes in the choices available against Integra’s drainage and monitoring devices.
Stryker competes with Integra for surgical customers through its MedSurg and Neurotechnology products. Watch sales in that business rather than its orthopaedics business for the closer read on competition facing Integra’s specialty surgical and neurosurgical products.
MiMedx Group, Inc competes with Integra for providers buying skin substitutes and tissue products for wounds, burns and surgical repair. Its expansion from donated placental tissue into animal-derived products broadens the alternatives to Integra’s wound-repair materials.
Smith & Nephew competes with Integra for wound-treatment providers’ purchases of advanced wound-care products and skin substitutes. Its work with healthcare customers on clinical evidence and reimbursement is worth watching where those customers choose between competing wound treatments.
ClearPoint Neuro, Inc. competes with Integra for hospitals buying systems that guide instruments to brain targets, as well as neurocritical-care drainage and monitoring devices. Watch its hospital installations and recurring disposable sales, rather than its drug-development services, for the more direct overlap with Integra.
Axogen, Inc. competes with Integra for reconstructive surgeons’ purchases of products that repair and protect peripheral nerves. Its U.S. sales of nerve grafts and Axoguard protection products are the clearest line to watch for this overlap.
Solventum competes with Integra for healthcare customers buying wound dressings and synthetic tissue materials for wound care and reconstruction. Look within its MedSurg business at those products; the segment also contains many other medical supplies.
Avita Medical, Inc. competes with Integra for providers treating burns and reconstructing full-thickness skin injuries. Watch its RECELL business in those uses: the system prepares a skin-cell suspension from a small sample of the patient’s own skin at the point of care.
TELA Bio, Inc. competes with Integra for plastic and reconstructive surgeons’ purchases: its OviTex PRS tissue matrices are alternatives to SurgiMend and DuraSorb. OviTex PRS sales are the relevant line to watch, rather than treating all of TELA Bio’s hernia-repair sales as the same competition.
Bioventus Inc. competes with Integra for surgical customers buying ultrasound-based systems, overlapping with Integra’s technology for removing tissue. Watch its neXus platform, which combines several ultrasonic surgical applications in one console, rather than its pain-treatment or fracture-care businesses.
Becton, Dickinson and Co. competes with Integra for healthcare institutions’ purchases of tissue-repair materials through its Bard products. Bard’s Phasix and Ventralight ST hernia meshes and GalaFLEX reconstructive product are more relevant to Integra than BD’s broader medical and laboratory sales.
Sanara MedTech Inc. competes with Integra for hospitals and surgical centers buying collagen, amniotic and other materials to manage surgical wounds and repair soft tissue. Watch its CellerateRX Surgical collagen powder and TEXAGEN amniotic membrane products for the closest overlap.
Vericel Corporation’s Epicel and Integra’s dermal regeneration products serve burn centers treating severe skin injuries. Watch Epicel sales to U.S. hospitals and burn centers: it treats deep-dermal or full-thickness burns covering at least 30% of a patient’s total body surface area.
Integra LifeSciences Holdings earningsThis company
Integra’s report will show whether growth in neurosurgery can hold up and its tissue business can recover from quality and operational problems.
Read CSS and TT revenue changes alongside gross margin. If CSS keeps growing as acquisition timing and prior-year shipping holds become less important, while TT improves and margin stabilizes, the business is building a firmer base. If CSS growth fades, TT keeps shrinking, or margin falls further, quality, supply and manufacturing costs are still weighing on results. The conclusion is whether Integra is turning sales growth into steadier operations.
Axogen, Inc. earningsAXGN
Axogen’s report will show whether U.S. sales of its nerve grafts and protection products are gaining ground against Integra’s offerings for nerve repair.
Watch sales of Axogen’s peripheral nerve grafts and protection products. Stronger sales would show that reconstructive surgeons are buying these competing nerve-repair options, sharpening the competitive pressure on Integra; weaker sales would point to less momentum for them. For Integra, this is a read on competition in nerve repair, not direct evidence of its own sales.
ClearPoint Neuro, Inc. earningsCLPT
ClearPoint Neuro’s report will show whether hospitals keep installing its brain-targeting systems and buying the related disposables, an overlap with Integra’s hospital business.
Read system installations alongside recurring disposable sales. More installations with stronger disposable sales would show hospitals are both adopting and using this competing approach, making competition for Integra’s hospital customers more active; weakness in both would suggest limited uptake. For Integra, this signals the level of competition in the shared hospital market, not lost orders.
MiMedx Group, Inc earningsMDXG
MiMedx’s report will show whether providers are buying more wound and tissue products that compete with Integra’s wound-repair materials.
Watch sales of MiMedx’s wound and tissue products. Stronger sales would show providers spending more on alternatives to Integra’s wound-repair materials, potentially raising competitive pressure; weaker sales would suggest less traction for those alternatives. For Integra’s Tissue Technologies business, this reveals the direction of shared customers’ purchasing, but does not by itself prove a change in market share.
Fed Interest Rate Decision
Integra’s Fed rate decision matters because it signals whether borrowing costs are rising or falling, which can change interest paid on its term loan and revolving debt and leave more or less cash for operations and investment.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest on Integra’s debt as it reprices and make new borrowing more expensive, leaving less cash for operations and investment.
If it comes in below expectations
Lower rates can reduce interest on Integra’s debt as it reprices and make new borrowing cheaper, leaving more cash for operations and investment.
Bioventus Inc. earningsBVS
Bioventus’s report will show whether surgical customers are adopting its neXus ultrasonic platform, which competes with Integra’s tissue-removal technology.
Look for Bioventus’s discussion of neXus sales or customer adoption. Stronger uptake would show surgical customers are choosing a platform that combines ultrasonic applications, adding an alternative to Integra’s tissue-removal technology; limited uptake would point to less traction for this competitor. The conclusion is how strongly neXus is competing for these surgical purchases, not how Integra’s own sales changed.
Vericel Corporation earningsVCEL
Vericel’s report will show whether U.S. hospitals and burn centers are buying more Epicel, which competes with Integra’s dermal regeneration products for severe skin injuries.
Watch Epicel sales to U.S. hospitals and burn centers. Stronger sales would show providers are buying more of this alternative for severe burns, increasing direct competition for Integra’s dermal regeneration products; weaker sales would suggest less purchasing momentum for Epicel in these cases. For Integra, this is a signal about competition in severe skin-injury care, not proof that patients or orders shifted.
TELA Bio, Inc. earningsTELA
TELA Bio’s report will show whether plastic and reconstructive surgeons are buying more OviTex PRS, a direct alternative to Integra’s SurgiMend and DuraSorb.
Focus on OviTex PRS sales, not all of TELA Bio’s hernia-repair business. Growth would show plastic and reconstructive surgeons buying more of a competing tissue matrix, putting greater pressure on Integra’s SurgiMend and DuraSorb; weak sales would suggest the alternative is not gaining much adoption. The conclusion is how competition is changing for Integra in these reconstructive procedures.
Medtronic plc earningsMDT
Medtronic’s report will show whether providers are buying more devices to drain brain fluid and monitor pressure, competing with Integra for hospital spending.
Watch Medtronic’s discussion of sales or adoption for its ventricular-drainage and pressure-monitoring products. Stronger purchasing would show hospitals spending more on these neurosurgical devices, intensifying competition for Integra’s drainage and monitoring products; weaker purchasing would suggest less momentum for this competing line. For Integra, this shows how hospital choices in these devices are shifting, not whether its own orders rose or fell.
